title: Corynebacterium urealyticum (CDC Group D2) associated with staghorn calculus: treatment by percutaneous debulking and chemolysis.
abstract: We report the formation of a staghorn calculus in a transplanted kidney caused by infection with a urea-splitting Corynebacterium group D2 organism. The stone was debulked percutaneously followed by intravenous vancomycin administration and urinary acidification with oral acetohydroxamic acid, leading to clearance of nearly all of the stone.
authors.affiliation: Division of Urology, Washington University School of Medicine, St. Louis, Missouri, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Nadler
authors.forename: T A
authors.initials: TA
authors.lastname: Hoffman
authors.forename: B L
authors.initials: BL
authors.lastname: McClennan
authors.forename: R V
authors.initials: RV
authors.lastname: Clayman
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003352:Corynebacterium / Q000302:isolation & purification*; D003354:Corynebacterium Infections / Q000150:complications* / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D007669:Kidney Calculi / Q000382:microbiology / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D009403:Nephrostomy, Percutaneous / Q000379:methods*; D011183:Postoperative Complications / Q000382:microbiology / Q000628:therapy*; D012086:Reoperation; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D006877:Hydroxamic Acids; C006358:acetohydroxamic acid; D014640:Vancomycin